Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet administration timing in hemodialysis patients with secondary hyperparathyroidism
2004-002310-10Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cinacalcet in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) (2 arms), sponsored by Amgen. Primary endpoint: Primary endpoint: iPTH response. Started Nov 2004; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2004-002310-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002310-10.